RP Cure Tracker

Trials / NCT01256697

The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa

Completed N/A Supplement / diet, Drug / neuroprotection

Sponsor
Sheba Medical Center
Treatment
Alga Dunaliella Bardawil; Alga Dunaliella Bardawill; Sugar pill
Gene
Not stated
Conditions
Retinitis Pigmentosa
Ages
18 Years to no upper limit
Enrollment
34 participants
Started
2008-08
Main results expected
2009-04
Results posted
Not yet
Record last updated
2013-12-20

What the study is testing

Retinitis pigmentosa is a genetically determined disease consisting of progressive centripetal retinal degeneration starting in the rods outer segments. Its prevalence is 1:4000 people and is the fourth most common blinding disease in Israel in 2004 [7% of all blindness]. The investigators tried to treat a non-progressive form of the disease [Fundus Albipunctatus] by oral therapy of the food supplement made from alga Dunaliella bardawil composed of approximately 50% 9-cis β-carotene. The alga Dunaliella bardawil accumulates high concentration of β -carotene when grown under appropriate conditions. The β -carotene of the alga is composed of approximately 50% of all-trans - β carotene and 50% 9-cis β -carotene.

The 9-cis β -carotene has shown to be a precursor of 9-cis retinoic acid both in-vitro in human intestinal mucosa and in-vivo in a ferret, perfuse with 9-cis b-carotene. The night vision, as measured objectively by electroretinography (ERG) more than doubled in six patients tested. The visual field was also improved significantly.

Where it runs

Israel (1)

Open on ClinicalTrials.gov for contacts and eligibility